The Janus face of proliferating plasmablasts in dengue and COVID-19 infections.

B-cells COVID-19 activation dengue inflammation memory naive plasmablasts

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 12 10 2022
accepted: 20 07 2023
medline: 29 8 2023
pubmed: 28 8 2023
entrez: 28 8 2023
Statut: epublish

Résumé

B cells play an integral role in the immune response to both dengue fever and COVID-19. Prior scRNAseq analyses of peripheral plasmablasts in COVID-19 have revealed a heterogeneous population with distinct cell subsets associated with proliferation; prior studies in patients with dengue fever have likewise shown the presence of proliferative pre-plasmablasts in the circulation. These findings may have implications for disease severity. In this study, we sought to gain a mechanistic understanding of the intracellular processes in naive and memory B cells that are associated with and may lead to an expanded proliferative plasmablast population in the circulation. We analyzed age-controlled (pediatric and adult), peripheral blood mononuclear cell scRNAseq datasets from patients infected with either dengue (primary or secondary) or COVID-19 (non-severe or severe) from previously published studies. Our preliminary analysis showed that pediatric patients with dengue and adults with COVID-19 had an expanded proliferative plasmablast (p-PB) population. By contrast, neither the adults with dengue nor the children with COVID-19 in our dataset had p-PBs. We used this distinctive preliminary signature to guide our analyses design and expanded our analyses to naive and memory B cells. In age/disease conditions with and without p-PBs, we found differences in cell sensing and activation, including via the B cell receptor and downstream signal transduction. Likewise, inflammation was mediated differently: relative to groups without p-PBs, those with p-PBs had increased expression of interferon response and S100 genes (particularly severe COVID-19). Furthermore, several transcription factors at the nexus of activation, inflammation, and cell fate decisions were expressed differently in groups with and without p-PBs. We used dengue and COVID-19 infections in adult and pediatric patients (focusing on naive B, memory B, and plasmablast cells) as a model to better understand the mechanisms that may give rise to p-PB populations in the circulation. Our results indicate that a more pro-inflammatory state in naive and memory B cells correlated with - and could influence the generation of- proliferating plasmablasts. Further exploration of these mechanisms will have implications for immune memory, vaccine development, and post-viral autoimmune syndromes.

Identifiants

pubmed: 37638019
doi: 10.3389/fimmu.2023.1068424
pmc: PMC10450630
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1068424

Subventions

Organisme : NLM NIH HHS
ID : R01 LM012595
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL108735
Pays : United States

Informations de copyright

Copyright © 2023 Nayak, Mukund and Subramaniam.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Immunol. 2014 Dec 1;193(11):5370-8
pubmed: 25411432
Clin Infect Dis. 2021 Sep 7;73(5):e1219-e1221
pubmed: 33373433
J Exp Med. 2015 Jan 12;212(1):53-72
pubmed: 25547673
J Immunol. 2002 Aug 15;169(4):1922-9
pubmed: 12165517
J Immunol. 2013 Jun 1;190(11):5526-33
pubmed: 23616571
Cell. 2021 Apr 1;184(7):1895-1913.e19
pubmed: 33657410
Trends Immunol. 2022 Mar;43(3):210-229
pubmed: 35090788
Comput Struct Biotechnol J. 2020 Dec 17;19:153-160
pubmed: 33425248
J Family Med Prim Care. 2020 Jan 28;9(1):293-297
pubmed: 32110607
Biochim Biophys Acta Mol Cell Res. 2020 Jun;1867(6):118677
pubmed: 32057918
Pathologe. 2021 Nov;42(Suppl 1):89-97
pubmed: 33950285
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Sci Rep. 2021 Apr 21;11(1):8570
pubmed: 33883570
Nature. 2022 Jun;606(7914):576-584
pubmed: 35385861
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D108-10
pubmed: 16381825
Cell Mol Immunol. 2021 Jul;18(7):1826-1828
pubmed: 34059791
Nat Rev Immunol. 2020 Oct;20(10):581-582
pubmed: 32839569
Immunity. 2020 Dec 15;53(6):1296-1314.e9
pubmed: 33296687
Am J Trop Med Hyg. 2005 Dec;73(6):1063-70
pubmed: 16354813
Front Med (Lausanne). 2021 Nov 03;8:738291
pubmed: 34805205
J Immunol. 2019 Oct 1;203(7):1687-1692
pubmed: 31484734
iScience. 2021 Apr 29;24(5):102482
pubmed: 34113823
Nat Rev Immunol. 2021 Apr;21(4):209-220
pubmed: 33024284
Eur J Immunol. 2013 Nov;43(11):2980-92
pubmed: 23857366
Nat Commun. 2022 Jan 10;13(1):80
pubmed: 35013199
J Formos Med Assoc. 2013 Jan;112(1):3-11
pubmed: 23332423
EBioMedicine. 2020 Apr;54:102733
pubmed: 32315970
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
Front Immunol. 2021 Nov 02;12:767981
pubmed: 34804055
Front Immunol. 2021 Oct 13;12:738073
pubmed: 34721400
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Am J Trop Med Hyg. 2020 Dec 15;104(2):487-489
pubmed: 33331264
J Immunol. 2015 Jun 15;194(12):5851-60
pubmed: 25972488
Exp Hematol Oncol. 2021 Jan 7;10(1):4
pubmed: 33413671
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Can J Microbiol. 2021 Oct;67(10):687-702
pubmed: 34171205
Front Immunol. 2018 Jan 05;8:1908
pubmed: 29379499
PLoS One. 2017 Aug 15;12(8):e0183268
pubmed: 28809949
Clin Infect Dis. 2021 Oct 5;73(7):e2444-e2449
pubmed: 32797228
iScience. 2022 Mar 05;25(4):104034
pubmed: 35345453
Leukemia. 2019 Aug;33(8):2047-2060
pubmed: 30755708
Cytometry A. 2020 Jul;97(7):662-667
pubmed: 32506725
Trends Immunol. 2019 May;40(5):431-446
pubmed: 30956067
Expert Rev Anti Infect Ther. 2015;13(12):1441-56
pubmed: 26536064
Nat Commun. 2021 Sep 14;12(1):5444
pubmed: 34521850
Nat Commun. 2021 Sep 14;12(1):5417
pubmed: 34521836
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488
iScience. 2021 Nov 19;24(11):103325
pubmed: 34723157
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12363-E12369
pubmed: 30530648

Auteurs

Priya Nayak (P)

Department of Bioengineering, University of California, San Diego, La Jolla, CA, United States.

Kavitha Mukund (K)

Department of Bioengineering, University of California, San Diego, La Jolla, CA, United States.

Shankar Subramaniam (S)

Department of Bioengineering, University of California, San Diego, La Jolla, CA, United States.
Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, United States.
Department of Computer Science and Engineering, University of California, San Diego, La Jolla, CA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH